. Cognitive-behavioral therapy for body dysmorphic disorder: A systematic review and meta-analysis of randomized controlled trials.
Introduction
Body dysmorphic disorder (BDD) is characterized by a persistent preoccupation with perceived defects or flaws in one"s appearance, which are unnoticeable to others (American Psychiatric Association, 2013) . This preoccupation leads to time-consuming rituals (e.g., mirror checking) and marked avoidance, which cause significant distress and impairment (Didie, Menard, Stern, & Phillips, 2008) , and results in poor quality of life (Phillips, 2000) .
BDD is also linked with strikingly high suicidal behavior (Phillips, Menard, Pagano, Fay, & Stout, 2006a; Phillips, 2005; Phillips et al., 2005) . Approximately one third of patients lack insight into their difficulties, which they attribute to objective physical flaws rather than being emotional in origin (Phillips et al., 2006b) . BDD is relatively common, with prevalence estimates ranging from 1.7% to 2.4% (Buhlmann et al., 2010; Koran, Abujaoude, Large, & Serpe, 2008; Rief, Buhlmann, Wilhelm, Borkenhagen, & Brähler, 2006) . The onset typically occurs during adolescence, with earlier onsets associated with a more insidious form of illness, a higher frequency of suicide attempts, and greater comorbidity (Bjornsson et al., 2013) . High comorbidity with major depressive disorder, social anxiety disorder, and obsessive-compulsive disorder (OCD), amongst others, is frequently reported (Gunstad & Phillips, 2003) .
BDD is unlikely to resolve without an evidence-based intervention (Phillips, Menard, Quinn, Didie, & Stout, 2013) . Two principal forms of treatment are thought to be efficacious for BDD, namely serotonin reuptake inhibitors (SRIs) and cognitive-behavior therapy (CBT) adapted for BDD and including exposure with response prevention (ERP) techniques.
Regarding pharmacotherapy, a limited number of double blind placebo-controlled trials have shown that clomipramine (relative to desimipramine; Hollander et al., 1999) and fluoxetine (relative to placebo; Phillips, Albertini, & Rasmussen, 2002) are efficacious in BDD, while SRI non-responders do not seem to benefit from augmentation with low doses of antipsychotics (Phillips, 2005) . A further relapse prevention trial has recently shown that, amongst responders to escitalopram, continuation of escitalopram was associated with lower relapse rates and longer time to relapse, compared to patients who were switched to placebo (Phillips et al., 2016) .
Regarding CBT, a previous meta-analysis (Ipser, Sander, & Stein, 2009 ) identified three randomized controlled trials (RCT)with available data for analyses from two studies (combined n = 36)and concluded that CBT significantly reduced BDD symptoms, relative to waitlist/no treatment conditions (Weighted Mean Difference = -44.96, 95% The primary aim was to investigate the efficacy of CBT for BDD through a systematic review and meta-analysis of all published and unpublished RCTs for individuals with BDD of all ages, with primary outcomes of treatment response determined using validated measures of BDD. As a secondary aim, the effect of CBT on depressive symptoms and insight in patients with BDD was investigated. The planned analyses also included metaregression to examine the potential effect of symptom severity, number of CBT sessions and therapy hours, comorbidities, insight, use of medication, previous cosmetic procedures, gender, age, and duration of the disorder on the outcomes studied.
Methods
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The review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and protocol outlined by the PRISMA Group (Moher, Liberati, Tetzlaff, & Altman, 2009 ).
Protocol and Registration
The protocol of this review was registered with the International Prospective Register for Systematic Reviews (PROSPERO), number CRD42015025513, available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025513.
Eligibility Criteria
Studies were eligible for inclusion if they: A) Included patients with a diagnosis of of Diseases (ICD) in its 9 th or 10 th editions (World Health Organisation, 1975 , 1999 ; B)
reported results of an RCT evaluating the efficacy of CBT (in all its varieties and formats) against a waitlist/no treatment, treatment as usual, other psychotherapies, or a credible psychological placebo; and C) contained sufficient data for analyses. No language or age restrictions were set.
Information Sources
Two of the authors (AH and LFC) conducted an independent systematic two-step literature search to identify relevant articles. First, EMBASE, MEDLINE®, and PsycInfo were searched to detect published and unpublished studies on CBT for individuals with BDD.
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Databases were searched up to November 26 th 2015. Second, manual searches of the reference lists of previous reviews and the retrieved articles were performed. Additionally, research teams in the field were contacted for unpublished RCTs, as were the contacts for the registered incomplete trials reported in the previous review (Ipser et al., 2009 ).
Search
The search was performed in the above-mentioned databases using the Ovid® search 
Study Selection
Abstracts were initially screened to ascertain whether the reported study met the eligibility criteria described above. If eligibility criteria were met, the full text article was retrieved and screened for the presence of sufficient data for analysis. Where this was not the case, the corresponding author of the article was contacted and data were requested.
The data extracted for the meta-analysis were taken from the controlled phase of the were offered after the primary endpoints, or patients in the waitlist/control groups were offered to crossover to CBT after the primary endpoint, these were not analyzed.
Data Collection Process
Data extraction and quality assessment were independently performed by two of the authors (AH and LFC). Disagreement between the two authors concerning the extracted data was resolved via discussion until a consensus was reached. Any uncertainty regarding the extraction of data from a particular study was resolved via contact with the study authors.
Data Items
For each article, pre-treatment, post-treatment, and follow-up (when available) means, standard deviations, effect sizes of the difference in severity decrease between CBT and the waitlist/control group were recorded for both primary and secondary outcomes. items objectively used to calculate the quality score of each study (see below).
Risk of bias in individual studies
The Cochrane Collaboration"s Tool for Assessing Risk of Bias (Higgins et al., 2011) was used to explore possible bias in the individual studies. Studies were assessed across five domains: adequate sequence generation, allocation concealment, outcome assessment blinding, management of incomplete outcome data and selective reporting. Each study was scored using a three-item scale (low, high, or uncertain risk of bias).
Summary Measures
Effect size of the difference in severity decrease between groups (Cohen"s delta, i.e. the standardized difference in mean decrease) was directly retrieved from the papers (Enander et al., In press; Veale et al., 2014; Wilhelm et al., 2014) or derived from the reported statistics (Rabiei, Mulkens, Kalantari, Molavi, & Bahrami, 2012) .
Two other papers (Rosen, Reiter, & Orosan, 1995; Veale et al., 1996) reported the pre-and post-treatment means and variances but not the pre-post correlation, which is needed to calculate Cohen"s delta. Rather than estimating a single constant correlation coefficient, the pre-post correlation coefficients were meta-analyzed using the MetaNSUE approach (Radua DISORDER 9 et al., 2015) , which yields multiple imputations of the (Fisher-transformed) unknown correlation coefficients according to the distribution parameters estimated from all other studies. Each set of imputed correlation coefficients was then used to create a set of imputed effect sizes. One study (Rosen et al., 1995) reported both the BDD-YBOCS and the BDDE;
before the final analysis, the separate effect-sizes resulting from both measurements were combined into a single one (Rubia et al., 2014) .
Synthesis of results
All effect sizes were corrected for small sample size (Hedges & Olkin, 1985) and
separately meta-analyzed in each set of imputations using random-effects (in case of main analyses) or mixed-effects (in case of meta-regressions) models, which take both intra-study and between-study variability into account. The latter, also called "heterogeneity," was estimated with the optimal restricted maximum likelihood (REML) technique (Viechtbauer, 2005) .
Consistency of these differences was assessed: a) estimating the percentage of variability due to between-study heterogeneity (I 2 ) and the probability that this is statistically significantly different from 0% (so-called "Q test", but using an F statistic due to the multiple imputations); and b) conducting leave-one-out jack-knife analyses (i.e. iteratively repeating the meta-analysis with all studies but one).
The multiple results originated from the different imputation sets were pooled taking imputation variability into account (Radua et al., In press ). To allow other researchers easily follow our approach, we modified MetaNSUE software to automatically conduct metaanalysis of effect size based on imputation of correlations coefficients (software available at
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Separate meta-analyses were also conducted for depressive symptoms and for insight scores, as well as for follow-up severity, although due to the lower number of studies (five, four, and three, respectively), complementary analyses other than the jack-knife iterations were not conducted.
Drop-out analysis
Possible differences in the number of patients who dropped out prematurely from treatment were investigated between the two arms. Analyses were then repeated considering drop-out patients as non-responders, as follows. First, a meta-analysis of the (logarithmtransformed) relative risk that a patient dropped out from the CBT group (as compared to the control group) was conducted. Second, post-treatment means and variances including dropout patients were estimated assuming post-treatment mean and variance in drop-out patients to be the same as pre-treatment mean and variance.
Risk of bias across studies
Funnel plots were used to explore the risk of publication or selective reporting bias and the possibility of missing studies. Potential bias was further assessed by meta-regressing the effect sizes by their standard errors in order to detect whether studies with larger standard errors (due to e.g. small sample sizes) report larger effect sizes.
Additional studies (meta-regression) 
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Both first authors had full access to all data in the study and had final responsibility for the decision to submit for publication.
Results
Study selection and study characteristics
The PRISMA flowchart is shown in Figure 1 . Seventeen studies out of a total 211 that were initially screened were analyzed for eligibility, leading to a total of seven studies finally included in the review, comprising 299 participants with BDD. All studies included adults with BDD except for Mataix-Cols et al., (2015) which included an adolescent sample. The majority of studies involved individually delivered face-to-face CBT sessions including ERP and differing amounts of additional cognitive techniques, compared to no treatment/waitlist (Rabiei et al., 2012; Rosen et al., 1995; Veale et al., 1996; Wilhelm et al., 2014) , an enhanced waitlist , or a credible psychological placebo (Enander et al., 2016; Veale et al., 2014) . One study compared meta-cognitive therapy based on Wells (2000) with a waitlist control and was the only RCT that did not explicitly mention ERP (Rabiei et al., A C C E P T E D M A N U S C R I P T
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COGNITIVE-BEHAVIORAL THERAPY FOR BODY DYSMORPHIC DISORDER 12 2012), although it included behavioural experiments. One study used a group format (Rosen et al., 1995) . Another study compared Internet-delivered CBT (including ERP) with Internetdelivered supportive therapy (Enander et al., 2016 ) (see Table 1 ). (Rabiei et al., 2012; Rosen et al., 1995; Veale et al., 1996; Wilhelm et al., 2014) and three were considered to have low risk of bias (Enander et al., 2016; Veale et al., 2014) .
Risk of bias within studies
Results of individual studies and synthesis of results
The final sample of the meta-analysis consisted of seven RCTs, totaling 299
individuals. At post-treatment, improvement on the primary outcome measure was significantly higher in patients receiving CBT than in patients on a waitlist or control treatment (delta = -1.22, 95% CI = -1.66 to -0.79; p < 0.001; Figure 2 ). There was moderate heterogeneity (I 2 = 54%), but this did not reach statistical significance (F = 1.3; p = 0.277).
Jack-knife sensitivity analyses showed that the exclusion of any single study from the analysis did not result in any meaningful differences in the overall effect size (Table 3) .
Controlled follow-up data was only available for three studies (Enander et al., 2016; Rabiei et al., 2012) . CBT remained superior to waitlist/control treatment 2 to 4 months after treatment (delta = -0.89, 95% CI = -1.24 to -0.54; p < 0.001).
CBT was also associated with significant improvements in comorbid depression studies] = -0.49, 95% CI = -0.76 to -0.22; p < 0.001, Figure 3 ; insight delta [4 studies] = -0.56, 95% CI = -0.93 to -0.19; p = 0 .003, Figure 4 ). Jack-knife analysis showed that these results were robust, that is, not driven by the effects of any single study (Table 3) . Depression and insight/delusionality symptoms were not assessed at follow-up given that only two studies 30,31 reported follow-up data.
Drop-out analysis
No differences in the number of drop-out patients were detected between the CBT and waitlist/control groups (relative risk = 1.01, 95% CI = 0.97 -1.05; p = 0.772), and the results of the meta-analyses were similar when considering drop-out patients as non-responders (BDD severity: delta = -1.25, 95% CI = -1.84 to -0.65; p<0.001; depression: delta = -0.37, 95% CI = -0.70 to -0.02; p = 0.036; insight: delta = -0.53, 95% CI = -0.85 to -0.21; p = 0.001).
Risk of bias across studies
Inspection of the funnel plot ( Figure 5 ) showed potential reporting bias, though regression by standard error was not significant (p = 0.238).
Additional analyses (meta-regression)
None of the regressors investigated were predictive of changes in BDD severity across studies. Too few studies were available for analysis of the secondary outcome variables.
A C C E P T E D M A N U S C R I P T
Discussion
The main finding of this meta-analysis was that CBT is an efficacious intervention for treating the main symptoms of BDD and some of its accompanying features (depressive symptoms and insight/delusionality). The meta-analysis also showed that gains are likely to be maintained at least in the short term (2-4 months after treatment therapy-based ERP, meta-cognitive therapy with no explicit ERP), methods of treatment delivery (individual, group, Internet-based), and age groups (adults, adolescents), the results were remarkably robust; exclusion of any given study at a time did not substantially modify the overall effect sizes. This suggests that CBT is probably suitable across a range of individuals and robust to the method of delivery, though the evidence for adolescents, group CBT, and Internet-based CBT is limited to single trials.
Employing the widely-used criteria suggested by (Chambless & Hollon, 1998) , CBT for BDD can be said to be efficacious and possibly specific. Under this framework,
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efficacious means that two or more independent research groups have found that the treatment is superior to no treatment or waitlist, and possibly specific means that CBT is probably superior to generic psychological treatment. We conservatively considered that only one study to date (Veale et al., 2014 ) employed a truly credible control treatment. Therefore, additional trials are required to test the specificity of CBT for BDD.
These generally optimistic results need to be tempered by having a closer look at the percentage of patients who achieved responder status in these trials. Four of the seven studies reported a percentage of responders using an empirically derived cut-off of at least 30% change on the BDD-YBOCS (Phillips, Hart, & Menard, 2014) ; 40% to 54% of patients were classified as responders, which is a substantially lower response rate than that typically obtained in CBT trials for OCD, where response rates range between 60% and 80%, depending on how response is defined (Mataix-Cols et al., 2016; Öst et al., 2015) . Many participants had post-treatment severity scores in the mild/moderate range, which means that they would normally qualify for entry into a BDD clinical trial. It is also our clinical impression that many patients with BDD would drop out from treatment in naturalistic settings, compared to the "hot pursuit" strategies employed in clinical trials of either CBT or pharmacotherapy. In a naturalistic 4-year prospective follow-up study of 166 patients with BDD, the cumulative probability of being in full remission was 0.20 .
This, coupled with the fact that many BDD patients may refuse or are unable to engage in CBT due to low insight, low mood, imminent suicide risk, or other reasons, suggests that there is significant room for improvement and that CBT may not be the best or single treatment option for all patients with BDD.
Clearly, there is further room to improve on the existing CBT protocols. For example, some patients may require a higher number of sessions. There is some uncontrolled trial data to suggest that adding additional sessions (beyond the standard 8-14 sessions employed in
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previous trials) may lead to further improvement in BDD symptoms (Veale et al., 2014; Wilhelm et al., 2014) . At present, there is insufficient data to suggest that any particular modality of CBT is superior to another. Like in OCD (Öst et al., 2015; Ponniah et al., 2013) , both exposure-based and cognitive interventions may be comparably efficacious for BDD, arguably because these interventions may address the same maintaining factors (e.g., avoidance). Dismantling studies may be helpful to determine, for example, if adding cognitive techniques (such as metacognitive tools; Rabiei et al., 2012) enhances the efficacy of more purely behavioral interventions. As mentioned earlier, further studies comparing CBT with credible control treatments are needed to establish the specificity of this treatment.
Long-term follow-ups of CBT-treated BDD patients are rare (McKay, 1999; Veale, Miles, & Anson, 2015) . These follow-up studies suggest that many patients maintain their gains but longer follow-up studies are needed to confirm this. The optimal strategies, pharmacological or psychological, for patients who require additional treatment after a course of CBT are unclear. Similarly, sequential trials of SSRI-resistant patients are needed to evaluate whether CBT offers additional clinical benefit, as it has been demonstrated in OCD (Franklin et al., 2011; Simpson et al., 2008) . Unfortunately, no reliable predictors of outcome have been identified in BDD to guide clinical decision-making.
While the results broadly support the NICE guidelines, they do not inform clinicians as to which patients should be offered CBT and which should be offered a combination of CBT and SRI. Severity alone does not seem a reasonable criterion, since many patients included in the CBT trials were in the severe range, and severity did not reliably predict outcome. Trials comparing the efficacy and safety of CBT, SSRIs, and their combination are needed.
CBT for adolescents with BDD has only been tested in one small RCT, which compared developmentally tailored CBT with an enhanced waitlist control consisting of written psychoeducation materials and weekly phone calls to monitor risk . Since approximately 70% of patients report symptom onset during adolescence (Bjornsson et al., 2013) , further trials are warranted in this age group, preferably in the incipient phases of the disorder, with the aim of preventing school failure, suicide risk, and chronicity. Unfortunately, the disorder often goes undetected in young people, as the symptoms of BDD may be mistakenly interpreted as normal developmental concerns (i.e., most teenagers worry about their appearance to some extent). More must be done to improve early detection and diagnosis of BDD in young people, particularly boys .
The development and evaluation of Internet-based interventions for BDD is an
emerging area that should be explored further. Data from a relatively large RCT (Enander et al., 2016) suggest that this can be a highly acceptable, safe, and efficacious way to reach a large majority of patients previously unable to access CBT. However, this may only be an option for less severe patients who have reasonably intact insight and are therefore motivated for treatment. Internet-based CBT may particularly useful in a stepped-care model, where mild to moderate cases could be offered the treatment by general practitioners, thus freeing resources for more severe and complex cases to be treated in specialized settings. Future stepped-care trials of Internet-based CBT in non-specialist settings are warranted. There is also preliminary evidence to support the efficacy of group-based CBT for BDD (Linde et al., 2015; Rosen et al., 1995) , which has the potential to be cost-effective in specialist settings and should be evaluated further.
This study has several limitations. First, the studies included in the meta-analysis used a range of manualized CBT-based treatments with a degree of heterogeneity in the content and format of the CBT offered to patients. Similarly, control conditions were also heterogeneous, with most studies using a waitlist as a control, but others using a more active control like anxiety management (Veale et al., 2014) or supportive therapy (Enander et al., 2016) . However, despite this heterogeneity, jack-knife analyses indicated no significant differences in overall impact relative to the studies included in the meta-analysis, and a key common treatment component was ERP in all studies, with one exception (Rabiei et al., 2012) in which CBT was focused on developing metacognitive skills. Second, the current evidence is based on seven RCTs worldwide, including fewer than 300 patients, and conducted primarily in specialist clinics. This may potentially limit the generalizability of the results to other settings and to other populations systematically excluded form clinical trials, such as those with certain comorbididities (e.g., substance use disorders) or acute suicidal behavior. Results on secondary outcomes, namely depressive symptoms and insight/delusionality, should especially be interpreted with caution as they were based on reports in five and four studies, respectively. Given the relatively small sample, future metaanalyses of individual participant data may be helpful to further increase power and better control for potential confounds (Stewart et al., 2015) . Finally, several studies failed to report on the ethnic background of their participants; over 80% of patients included in the trials that reported this information were from White backgrounds and, thus, it is unclear whether CBT is equally acceptable and efficacious in patients from ethnic minorities.
Conclusions
CBT is an efficacious treatment for BDD symptoms and associated features, but there is substantial room for improvement. The specificity and long-term effects of CBT in both (Higgins & Green, 2011 
